Forte Biosciences, Inc., formerly Tocagen Inc., is a clinical-stage biopharmaceutical company. The Company is focused on clinical program and developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients. It provides FB-401, which is a live biotherapeutic for the treatment of inflammatory skin diseases. FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.